Related Experiment Video
Updated: Aug 7, 2026
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Anti-restenosis Trials
1Thoraxcenter, University Hospital Rotterdam, Bd 410, PO Box 2040, Rotterdam 3000 CA, The Netherlands. defeyter@card.azr.nl
Insights
Restenosis after angioplasty remains a challenge, affecting 30-60% of patients. While stents help in some cases, in-stent restenosis and restenosis in long lesions or small vessels are still significant problems.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Device Technology
Background:
- Restenosis, the re-narrowing of arteries after angioplasty, affects 30-60% of patients, limiting long-term success.
- Pharmacologic agents have shown limited efficacy, with few drugs approved and ongoing trials for others.
- Stent implantation has improved outcomes for specific lesion types but has not resolved all restenosis issues.
Purpose of the Study:
- To review the current challenges and advancements in managing restenosis following percutaneous coronary angioplasty.
- To evaluate the effectiveness of different treatment modalities, including pharmacologic agents and stenting.
- To identify unresolved issues in restenosis treatment, particularly in-stent restenosis and specific lesion characteristics.
Main Methods:
- Review of clinical trials and existing literature on restenosis after percutaneous coronary angioplasty.
- Analysis of the impact of various pharmacologic agents on restenosis rates.
- Evaluation of the role and limitations of coronary stent implantation in preventing restenosis.
- Assessment of emerging therapies like brachytherapy for specific restenosis scenarios.
Main Results:
- Pharmacologic interventions have largely failed to effectively prevent restenosis, with limited exceptions and ongoing investigations.
- Coronary stenting has significantly reduced restenosis in specific patient groups and lesion types.
- In-stent restenosis remains a major challenge, often recurring after repeat interventions.
- Restenosis in long lesions and small vessels continues to be an unresolved clinical problem.
Conclusions:
- Despite advancements, restenosis after percutaneous coronary angioplasty persists as a significant clinical problem.
- Coronary stenting offers benefits but does not eliminate the risk, especially for in-stent restenosis.
- Further research and novel therapeutic strategies are needed to address persistent restenosis challenges, particularly in complex lesion subsets.
Abstract:
The high frequency of restenosis after percutaneous coronary angioplasty is still a major clinical problem. It occurs in 30% to 60% of patients and limits the long-term success of angioplasty. Many clinical trials have been conducted to resolve this problem, using a wide range of pharmacologic agents such as antiplatelet agents, anticoagulation drugs, lipid-lowering drugs, angiotensin-converting enzyme inhibitors, anti-inflammatory drugs, and antiproliferative drugs. Thus far, no effective drug has been reported, with the exception of probucol, which unfortunately is not approved by the US Food and Drug Administration because it prolongs the QT time, and possibly trapidil and cilostazol, two agents that are currently being tested in larger trials. Stent implantation has significantly reduced the frequency of restenosis in patients with 1) short lesions in large coronary arteries, (> 3.0 mm), 2) native coronary restenosis lesions, 3) venous bypass graft obstructions, 4) chronic total occlusions, and 5) acute myocardial infarction in patients referred for primary percutaneous intervention. A significant problem is the occurrence of in-stent restenosis because it is associated with a high recurrence of restenosis, after repeat coronary intervention irrespective of the technique or device used. Brachytherapy may limit this problem. The high restenosis rate occurring in long lesions and in small vessels still remains an unresolved issue.
